LifeVantage Corp (LFVN)
NASDAQ:LFVN
Want to see LFVN full AI Analyst Report?
Top Page
LifeVantage
(NASDAQ:LFVN)
Select Model
Select Model
Rating:63Neutral
Price Target:
$5.50
▼(-18.64% Downside)
Action:Reiterated
Date:05/09/26
LFVN’s score is driven primarily by mixed financial performance: exceptionally strong gross margins and an improved balance sheet are offset by volatile revenue, compressed earnings, and weaker cash conversion. Valuation is a clear positive (low P/E and solid dividend), while technicals show modest improvement but not a full long-term trend recovery. The latest earnings call was mixed-to-cautious, with lower-end guidance and significant YoY declines partially balanced by liquidity and shareholder returns.
Positive Factors
High Gross Margins
Sustained gross margins near 78–83% indicate strong product economics and pricing power in supplements/personal care. This durable margin base provides a buffer to absorb distribution and logistics inflation and underpins the firm's ability to fund marketing, R&D and channel incentives over the medium term.
Negative Factors
Material Revenue Decline
A sharp drop in revenue and falling active consultant counts in the Americas signal erosion of the core direct‑selling base. Because the model depends on distributor volume and reorders, persistent declines can materially reduce scale, weaken network effects and raise per-unit acquisition costs over several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins
Sustained gross margins near 78–83% indicate strong product economics and pricing power in supplements/personal care. This durable margin base provides a buffer to absorb distribution and logistics inflation and underpins the firm's ability to fund marketing, R&D and channel incentives over the medium term.
Read all positive factors
LifeVantage Key Performance Indicators (KPIs)
LifeVantage (LFVN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$70.77M
Dividend Yield2.81%
Average Volume (3M)223.47K
Price to Earnings (P/E)10.0
Beta (1Y)0.25
Revenue Growth-12.15%
EPS Growth-38.04%
CountryUS
Employees222
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)0.46
Shares Outstanding12,615,822
10 Day Avg. Volume114,681
30 Day Avg. Volume223,474
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)4.63
Price to Sales (P/S)0.70
P/FCF Ratio15.25
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue0.35
Enterprise Value/Gross Profit0.45
Enterprise Value/Ebitda7.28
Forecast
1Y Price Target
$5.00Price Target Upside-26.04% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.6
Revenue Forecast (FY)$185.87M
LifeVantage Business Overview & Revenue Model
Company Description
LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, ba...
How the Company Makes Money
LifeVantage primarily makes money by selling its health and wellness products through a direct selling (multi-level/affiliate-style) distribution network. Revenue is generated mainly from product sales to and through independent distributors (who ...
LifeVantage Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Aug 25, 2026
Earnings Call Sentiment Neutral
The call communicated a mixed picture: meaningful near-term financial headwinds with a 25.2% revenue decline, reduced profitability, and lower cash flow are offset by solid liquidity (no debt and $12.5M cash), active shareholder returns (buybacks and increased dividend), a newly granted patent, strategic acquisition (LoveBiome/P84), investments in Shopify and digital infrastructure, stronger field engagement initiatives (Momentum Academy and VIP program), and the appointment of an experienced incoming CEO. Management acknowledged recent underperformance and outlined concrete initiatives to restore growth and operational improvement.Positive Updates
Strong Balance Sheet and Liquidity
Cash of $12.5 million and no debt at quarter end, providing financial flexibility; generated $5.5 million of cash from operations in first nine months of fiscal 2026.
Negative Updates
Significant Revenue Decline
Net revenue of $43.7 million, down 25.2% versus $58.4 million in the prior year, primarily driven by decreased sales of the MINDBODY GLP-1 system and a drop in total active accounts.
Read all updates
Q3-2026 Updates
Positive
Negative
Strong Balance Sheet and Liquidity
Cash of $12.5 million and no debt at quarter end, providing financial flexibility; generated $5.5 million of cash from operations in first nine months of fiscal 2026.
Read all positive updates
Company Guidance
Management said it now expects to finish fiscal 2026 with revenue, adjusted EBITDA and adjusted diluted EPS close to the lower end of its previously issued guidance range; Q3 metrics included revenue of $43.7M (down 25.2% YoY), gross profit 79.0% (79.4% adjusted excluding a $183K MINDBODY allowance), adjusted EBITDA $3.2M (7.3% of revenue) versus $6.4M (11%) prior year, GAAP net income $1.4M ($0.11/diluted) and adjusted net income $1.5M ($0.12), commissions and incentive expense expected to be ~42.5% of revenue for the full year, SG&A $13.9M (31.7% of revenue), income tax $0.3M in Q3 with a fiscal 2026 effective tax rate guidance of ~18–20%, cash of $12.5M and no debt, cash from operations $5.5M for the first nine months (about $5M in Q3 and expected to be similar in Q4), capital expenditures $2.5M YTD with roughly $1M in the March quarter and near-term spend tied to the Shopify rollout before declining, $3.7M cash used for the LoveBiome acquisition, 206K shares repurchased for ~$1.0M in the quarter (250K/$1.6M YTD) with $59M remaining on a $60M buyback authorization, and a quarterly cash dividend of $0.05 per share (an 11% increase) payable 06/15/2026 to holders of record 06/01/2026.LifeVantage Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
72
Positive
Cash Flow
54
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 195.32M | 228.53M | 200.16M | 213.40M | 206.36M | 220.18M |
| Gross Profit | 152.62M | 183.67M | 158.72M | 170.01M | 168.26M | 181.99M |
| EBITDA | 9.41M | 15.36M | 7.91M | 7.84M | 7.96M | 21.07M |
| Net Income | 5.75M | 9.80M | 2.94M | 2.54M | 3.12M | 12.89M |
Balance Sheet | ||||||
| Total Assets | 62.13M | 71.96M | 60.30M | 66.12M | 70.71M | 78.73M |
| Cash, Cash Equivalents and Short-Term Investments | 12.48M | 20.20M | 16.89M | 21.61M | 20.19M | 23.17M |
| Total Debt | 10.21M | 11.68M | 13.61M | 13.09M | 15.76M | 18.18M |
| Total Liabilities | 28.79M | 37.32M | 34.31M | 31.47M | 39.19M | 41.92M |
| Stockholders Equity | 33.34M | 34.64M | 25.99M | 34.65M | 31.52M | 36.81M |
Cash Flow | ||||||
| Free Cash Flow | 3.77M | 10.51M | 9.95M | 3.76M | 6.43M | 6.43M |
| Operating Cash Flow | 6.51M | 11.88M | 12.20M | 6.83M | 7.96M | 7.96M |
| Investing Cash Flow | -6.48M | -1.37M | -2.25M | -3.06M | -1.53M | -1.53M |
| Financing Cash Flow | -9.88M | -7.60M | -14.42M | -2.36M | -8.95M | -8.95M |
LifeVantage Technical Analysis
Positive
6.76
Price Trends
4.83
Positive
5.11
Positive
7.09
Negative
Market Momentum
0.14
Negative
59.93
Neutral
79.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFVN, the sentiment is Positive. The current price of 6.76 is above the 20-day moving average (MA) of 5.29, above the 50-day MA of 4.83, and below the 200-day MA of 7.09, indicating a neutral trend. The MACD of 0.14 indicates Negative momentum. The RSI at 59.93 is Neutral, neither overbought nor oversold. The STOCH value of 79.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LFVN.
LifeVantage Risk Analysis
LifeVantage disclosed 50 risk factors in its most recent earnings report. LifeVantage reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
LifeVantage Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $384.23M | 20.53 | 12.30% | ― | 7.26% | 104.70% | |
63 Neutral | $70.77M | 10.01 | 17.78% | 2.81% | -12.15% | -38.04% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
60 Neutral | $1.29B | 6.17 | -43.03% | ― | 3.69% | -16.34% | |
54 Neutral | $346.00M | 10.34 | 2.03% | ― | 5.67% | -73.96% | |
46 Neutral | $70.21M | ― | -140.70% | ― | -10.00% | -98.14% |
* Consumer Defensive Sector Average
LFVN
LifeVantage
5.61
-6.76
-54.63%
HLF
Herbalife
12.43
5.77
86.64%
NATR
Nature's Sunshine Products
21.85
7.02
47.34%
HAIN
Hain Celestial
0.78
-1.09
-58.45%
USNA
USANA Health
18.74
-10.68
-36.30%
ABVE
Above Food Ingredients
0.57
-0.69
-55.00%
LifeVantage Corporate Events
Business Operations and StrategyExecutive/Board Changes
LifeVantage Announces CEO Retirement and Interim Leadership Transition
Positive
Apr 16, 2026
LifeVantage Corporation announced on April 16, 2026 that longtime executive Steven R. Fife will retire as president, chief executive officer and board member effective April 30, 2026, with director Michael Beindorff stepping in as interim CEO from...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.